BB Biotech

BB Biotech FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of BB Biotech (BION.SW) as of Oct 19, 2026 is 53.47 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 401.27 % — a change of -86.67% (lower).

FCF Conversion

53.47 %

YoY

-86.67%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of BB Biotech is 2025 53.47 % . FCF Conversion Rate (FCF/EBITDA) of BB Biotech was 2024 401.27 % . It decreases by -86.67% lower compared to the previous year.

The BB Biotech FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
100.00 CHF
Jan 1, 2019
31.74 CHF
Jan 1, 2020
37.97 CHF
Jan 1, 2021
100.00 CHF
Jan 1, 2022
100.00 CHF
Jan 1, 2023
-105.65 CHF
Jan 1, 2024
401.27 CHF
Jan 1, 2025
53.47 CHF
The BB Biotech FCF Conversion history
YEARFCF ConversionYoY
53.47 %-86.67%
401.27 %-479.82%
-105.65 %-205.65%
100.00 %0.00%
100.00 %+163.36%
37.97 %+19.63%
31.74 %-68.26%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BB Biotech Stock analysis

What does BB Biotech do? BB Biotech AG is a Swiss investment company specializing in biotechnology and life sciences. The company was founded in 1993 and has been listed on the SIX Swiss Exchange since 1995. BB Biotech AG primarily invests in publicly traded companies in Europe and North America that are active in the biotechnology and healthcare industry. The business model of BB Biotech AG is based on a combination of active portfolio management and long-term investment strategy. The company invests in stocks of biotechnology and healthcare companies that typically do not yet generate profits but are developing promising products or technologies. BB Biotech AG focuses on high portfolio diversification to minimize risk. BB Biotech AG is divided into three business areas: biotechnology, pharmaceuticals, and medtech. The emphasis is on biotechnology, where the company invests in stocks of well-known biotech companies such as Celgene, Gilead Sciences, Regeneron, and Biogen. In the pharmaceutical sector, BB Biotech AG invests in large pharmaceutical companies like Roche, Novartis, or Pfizer. In the medtech sector, the company invests in companies specializing in the development of medical devices and instruments, such as Intuitive Surgical or Neurocrine Biosciences. BB Biotech AG provides added value to its investors through continuous monitoring of the companies in the portfolio and risk management. The company ensures that investors are always informed about the latest developments in the biotechnology and healthcare industry and regularly publishes reports about the portfolio. The portfolio of BB Biotech AG consists of over 30 different biotech, pharmaceutical, and medtech companies. The main holdings of BB Biotech AG are Celgene, Gilead Sciences, Biogen, Incyte, Vertex Pharmaceuticals, Regeneron, and Neurocrine Biosciences. Celgene is one of the world's leading biotech companies specializing in the development of drugs against cancer and other serious diseases. Gilead Sciences is a biotech company specializing in the research of new therapies for the treatment of infectious diseases such as HIV and hepatitis. Biogen is a biotech company specializing in the treatment of neurological disorders such as multiple sclerosis. Incyte is a biotech company specializing in the development of drugs against cancer and inflammatory diseases. Vertex Pharmaceuticals is a biotech company specializing in the treatment of cystic fibrosis. Regeneron is a biotech company specializing in the development of drugs against eye diseases such as macular degeneration and other serious diseases. Neurocrine Biosciences is a medtech company specializing in the development of drugs against sleep disorders and other neurological diseases. BB Biotech AG is an important player in the market for biotechnology and healthcare investments. Through smart selection of investment targets and systematic risk monitoring, the company has enabled investors to achieve high returns with comparatively low risk. Due to these factors, it is now one of the most important holdings in the biotechnology and healthcare sector. BB Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BB Biotech stock

FCF Conversion Rate (FCF/EBITDA) of BB Biotech is 53.47 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of BB Biotech changed from 401.27 % to 53.47 %, representing a -86.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) BB Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s BB Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BB Biotech

All Key Metrics — BB Biotech